The first in a series of supplements to look at orphan drugs and rare disease, this issue covers contract research organisations (CROs) and trial design.
It looks at how niche CROs are helping pharma with orphan and ultra-rare drug trial designs, and surveys the functional service provision (FSP) model for working with CROs.
There’s also a focus on patient recruitment and pharma and biotech perceptions on working with patient groups on trials.
View: Orphan drugs and rare diseases: CROs and trial design
To coincide with the launch of this first orphan drugs and rare diseases supplement PMLiVE has also unveiled a dedicated online section for the area.
This showcases our orphan drug and rare disease content, splitting it up for easy navigation into sections on CROs and trial design, early access and regulation, strategic communications and value demonstration.
